X-Chem, a company focused on drug discovery services, and the Structural Genomics Consortium (SGC), a public-private partnership accelerating drug discovery through open science, have partnered to create new chemical tools to study human proteins.
Laverock Therapeutics, the gene editing-induced gene silencing platform for human therapeutic applications, has expanded its seed funding round to £13.5 million.
Eli Lilly has announced that the National Institute for Health and Care Excellence (NICE) has recommended mirikizumab for the treatment of adults with moderately to severely active Ulcerative Colitis (UC).
The Novo Nordisk Foundation is planning to build a €127 million ($135 million) facility in Denmark to speed up the development and manufacturing process for cell therapies for use in early clinical trials.
A rescue medication could help reverse the effect of the most powerful synthetic opioids including fentanyl if accepted by the US Food and Drug Administration (FDA).
This week's woman in science, is Maria Pereira, who leads the Innovation Hub at TISSIUM, a Paris-based medtech startup that develops solutions for tissue reconstruction.
The UK startup Broken String Biosciences has raised a $15 million Series A round to fund the development of a DNA sequencing platform that maps off-target DNA breaks resulting from genome editing technology.
The contract development and manufacturing organization (CDMO) Fujifilm Diosynth Biotechnologies has completed a UK manufacturing facility for the production of advanced therapies including viral gene therapies, oncolytic viruses and viral vaccines for...
The big pharma company Bristol Myers Squibb (BMS) has recruited contract manufacturing and development organization (CDMO) Samsung Biologics to manufacture a commercial antibody cancer treatment until 2030.
Global biopharmaceutical company Takeda is working to modernize its operations in order to better serve clinical trial sites, patients and sponsor outcomes.
Vaxess Technologies, a life sciences company developing a shelf-stable vaccine patch with potential for self-application, has announced an additional $9 million in venture capital funding, with investors including RA Capital, The Engine, and GHIC, and...
Arrowhead Pharmaceuticals has spotlighted the potential of RNA interference (RNAi) therapeutic candidates in the lungs, with a clinical late breaker and multiple pre-clinical presentations at this year’s European Respiratory Society (ERS) International...
Kuano, a drug discovery company combining quantum mechanics with AI, has announced the close of its £1.8 million seed funding round, led by Mercia Ventures, and including ACF Investors, Ascension Ventures, o2h Ventures, Meltwind Advisory LLP, and other...
TherageniX, a University of Nottingham spin out pioneering a dry powder gene therapy formulation for bone graft augmentation, has been awarded a £995,000 grant from Innovate UK.
BioNTech and Pfizer have received a positive opinion from The Committee for Medicinal Products for Human Use (CHMP) for their updated COVID-19 vaccine, as a single dose for individuals 5 years of age and older, regardless of prior vaccination history,...
Huadong has been granted exclusive rights in Greater China to develop and commercialize MC2’s drug, Wynzora Cream, for the treatment of plaque psoriasis.
Intellegens, a company applying machine learning (ML) to accelerate innovation in R&D, has secured a £1.6m grant from Innovate UK, to apply ML in the emerging field of oligonucleotide therapies.
Quest Diagnostics, a provider of diagnostic information services, has announced that its AAVrh74 ELISA assay (CDx) has been granted breakthrough device designation from the U.S. Food and Drug Administration (FDA).
Optibrium, a developer of software and AI solutions for drug discovery, has acquired BioPharmics in a view to expand its 3D drug design and modelling offering.
GEDiCube is joining NVIDIA Inception, a program which guides start-ups by providing access to cutting-edge technology, technical resources, and venture capitalists.
The FDA recently granted approval for Johnson & Johnson’s (J&J) Akeega, a novel first-in-class combination tablet treatment for adults with breast cancer gene (BRCA)-positive, metastatic castration-resistant prostate cancer (mCRPC).
Kiora Pharmaceuticals has been granted US and European patents covering local ocular delivery of the KIO-100 family of non-steroidal, anti-inflammatory small molecules.
Cell and Gene Therapy Catapult, Rentschler Biopharma, and Refeyn have announced a new partnership to develop and apply ‘innovative’ process analytical technologies (PAT) to improve the process and efficiency of AAV manufacture.
LEO Pharma has acquired Timber Pharmaceuticals, in a deal that will add an ‘attractive’ late stage asset to its pipeline in medical dermatology, the company said.
Actimed Therapeutics Ltd will put some of its additional funding of £4.75 million ($6 million) towards its attempt to provide the world’s first cure for cancer cachexia.
Absci, a leader in AI drug creation, and the California Institute of Technology (Caltech) have received a grant from the Bill & Melinda Gates Foundation.
A new treatment for erectile dysfunction (ED) has received regulatory approval in the Kingdom of Saudi Arabia, a key ED market, with 10.45% of married males experiencing the condition.
Teknova, a producer of life science reagents, has opened a new GMP-certified production facility which it claims will enable bioprocessing and gene therapy companies to get into the clinic faster.
AGC Biologics, a global contract development and manufacturing organization (CDMO), has completed the expansion of its manufacturing space at its Milan Cell and Gene Center of Excellence production site.
A new report from Angelini Pharma has highlighted an ongoing treatment gap for epilepsy care in Europe, including significant differences in access to treatment between countries.
NK:IO, a leader in natural killer (NK) cell biology applied to the development of potent, off-the-shelf cell therapies targeting solid tumors, has raised £1.2m.
Renaissance Pharma, a company focused on the development of life changing therapies in pediatric rare disease, has entered into an exclusive license agreement with St. Jude Children’s Research Hospital for Hu14.18, a humanised antibody in development...
Bora Pharmaceuticals, an international contract development and manufacturing organization (CDMO), has announced the opening of a new state-of-the-art facility in Taoyuan City, Taiwan.
Biovian, a leading contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals, has announced a major investment of over €50 million to expand its manufacturing facility in Turku, Finland.
ImmunoGen, a biotech company focused on the development of antibody-drug conjugate (ADC) technology to treat cancer, has announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem, a biopharma firm...
Teva Pharmaceuticals, a provider of generic and innovative medicines, and Alvotech, a biotech company specializing in the development and manufacture of biosimilar medicines, have expanded their existing partnership agreement.
LinKinVax, a clinical-stage biotech company, has announced the manufacture and bottling of a GMP batch of its next generation pan-sarbecovirus vaccines, known as PanCov, designed to prevent COVID-19 and other known coronavirus diseases.
Janssen Pharmaceuticals has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional marketing authorisation for Talvey (talquetamab).